MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer
Volume: 131, Issue: 11, Pages: 2710 - 2716
Published: Apr 27, 2012
Abstract
Conflicting reports exist regarding the contribution of SNP309 in MDM2 to cancer risk. Recently, SNP285 was shown to act as an antagonist to SNP309 by overriding the effect of SNP309 on SP1‐mediated transcription. Moreover, SNP285 modified the relationship between SNP309 and risk of breast, ovarian and endometrial cancer. We assessed whether SNP285 confounded the effect of SNP309 in lung cancer in a cohort of 720 controls and 556 cases. Our...
Paper Details
Title
MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer
Published Date
Apr 27, 2012
Volume
131
Issue
11
Pages
2710 - 2716
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History